We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
+12.02%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$1.02B
AUM Growth
+$115M
Cap. Flow
+$23.9M
Cap. Flow %
2.35%
Top 10 Hldgs %
71.39%
Holding
43
New
3
Increased
7
Reduced
9
Closed
5

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$93.8M
2
ILMN icon
Illumina
ILMN
+$34.2M
3
BLFS icon
BioLife Solutions
BLFS
+$11.8M
4
NTLA icon
Intellia Therapeutics
NTLA
+$7.82M
5
NGNE icon
Neurogene
NGNE
+$7.51M

Top Sells

Rank Stock Value
1
EQRX
EQRx, Inc. Common Stock
EQRX
+$87.8M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$21.7M
3
GPCR icon
Structure Therapeutics
GPCR
+$9.53M
4
MXCT icon
MaxCyte
MXCT
+$5.9M
5
BPMC
Blueprint Medicines
BPMC
+$2.92M

Sector Composition

Rank Sector Weight
1 Healthcare 99.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CDXS icon
26
Codexis
CDXS
$156M
$6.1M 0.6%
2,000,000
+1,700,000
+567% +$3.65M
TSVT
27
DELISTED
2seventy bio
TSVT
$5.05M 0.5%
1,182,623
-841,290
-42% -$2.59M
ABSI icon
28
Absci
ABSI
$1.34B
$4.09M 0.4%
973,260
– –
ILMN icon
29
CALL
Illumina
ILMN
$30B
$3.48M 0.34%
25,700
– –
PRME icon
30
Prime Medicine
PRME
$508M
$3.25M 0.32%
367,175
– –
SNDX icon
31
Syndax Pharmaceuticals
SNDX
$1.7B
$3.24M 0.32%
+150,000
New +$2.31M
GLUE icon
32
Monte Rosa Therapeutics
GLUE
$1.3B
$2.89M 0.28%
510,882
– –
LAB icon
33
Standard BioTools
LAB
$339M
$2.65M 0.26%
1,200,000
– –
EXAI
34
DELISTED
Exscientia Plc American Depositary Shares
EXAI
$1.37M 0.13%
213,900
– –
GPCR icon
35
CALL
Structure Therapeutics
GPCR
$3.44B
$1.02M 0.1%
+25,000
New +$1.43M
LIAN
36
DELISTED
LianBio American Depositary Shares
LIAN
$923K 0.09%
206,415
– –
OMIC
37
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$609K 0.06%
44,130
– –
KRON
38
DELISTED
Kronos Bio
KRON
$155K 0.02%
123,839
– –
ALNY icon
39
CALL
Alnylam Pharmaceuticals
ALNY
$29.5B
– –
-20,000
Closed -$3.54M
MXCT icon
40
MaxCyte
MXCT
$115M
– –
-1,890,000
Closed -$5.9M
SANA icon
41
Sana Biotechnology
SANA
$885M
– –
-750,000
Closed -$2.9M
MRTX
42
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-498,427
Closed -$21.7M
EQRX
43
DELISTED
EQRx, Inc. Common Stock
EQRX
– –
-39,527,669
Closed -$87.8M
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return
WGAM
Wilkinson Global Asset Management New York $1.31B AUM 17.03% 1-Year Est. Return
CRAM
Compass Rose Asset Management New York $1.33B AUM 2.38% 1-Year Est. Return

Casdin Capital's Q4 2023 Portfolio in Review

As of Q4 2023, Casdin Capital held 43 positions worth $1.02B, up 13% from $904M the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Casdin Capital's Q4 2023 filing shows 3 new, 7 increased, 9 reduced and 5 closed positions. Its largest new stake was Neurogene: 524,616 shares worth $10.2M. The largest sale was EQRx, Inc. Common Stock, an estimated $87.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

  • Casdin Capital's largest Q4 2023 buy was Neurogene: 524,616 shares worth $10.2M.
  • Casdin Capital added most to Revolution Medicines in Q4 2023, an estimated $93.8M increase.
  • Casdin Capital's biggest Q4 2023 reduction was Structure Therapeutics, cutting an estimated $9.53M.
  • Casdin Capital fully exited EQRx, Inc. Common Stock in Q4 2023, selling an estimated $87.8M.
  • Casdin Capital's ten largest holdings make up 71% of its $1.02B portfolio in Q4 2023.
  • Casdin Capital opened 3 new positions and closed 5 in Q4 2023.
  • Casdin Capital's portfolio value rose 13% quarter-over-quarter to $1.02B.

Based on Casdin Capital's 13F filing for Q4 2023, filed 14 Feb 2024.